Citations

Mayo Clinic

Showing 10 of 108537 citations.

Use of ultrasound gel to mitigate risks of skin burns from non-actively cooled mic rowave applicators
Ren, Liqiang , Woodrum, David A. , Gorny, Krzysztof R. , Felmlee, Joel P. , Thompson, Scott M. , Xi, Yin, Lu, Aiming , Adamo, Daniel A.

American Journal of Interventional Radiology | May 9, 2024 | Volume: 8 | Issue: No issue available | Pages: 5

10.25259/ajir_3_2024 Get It

The purpose of this study is to investigate the potential of using ultrasound gel to mitigate the risks of skin burn at the insertion site during microwave ablation (MWA) using non-actively cooled applicators. Ex vivo experiments in porcine tissue were conducted using two identical MWA systems. Five MWA scenarios were tested at different applicator insertion depths with an ultrasound gel layer applied at the applicator insertion sites: 8 cm insertion depth with and without 4 cm thick gel, 10 cm insertion depth with and without 2 cm thick gel, and 12 cm insertion depth without gel (reference). In all experiments, temperature elevations at the applicator insertion site on the tissue surface were recorded using thermal sensors in all experiments during 10-min MWA. The application of ultrasound gel and increasing applicator insertion depths resulted in measurable reductions in temperature elevations at the applicator insertion sites. For an insertion depth of 8 cm, the temperature elevations were 39.9 ± 4.7°C and 23.2±6.5°C without and with gel, respectively (P < 0.001). For an insertion depth of 10 cm, the temperature elevations were 20.8 ± 1.5°C and 14.4 ± 1.5°C without and with gel, respectively (P < 0.001). The maximal temperature elevations corresponding to an 8 cm insertion depth with gel were comparable with those corresponding to a 10 cm insertion depth without gel. Similarly, the maximal temperature elevations (12.2 ± 1.8°C) corresponding to 12 cm insertion depth without gel were comparable to those corresponding to 10 cm insertion depth with gel. Applying ultrasound gel at the applicator insertion site can significantly reduce temperature elevations at the tissue surface during MWA procedures.
Long‐term pneumatic stenting with positive expiratory pressure therapy for severe expiratory central airway collapse
Funes‐Ferrada, Rodrigo , Lee‐Mateus, Alejandra Yu , Johnson, Margaret M. , Fernández-Bussy, Sebastián , Barrios-Ruiz, Alanna, Yu Lee-Mateus, Alejandra , Fernandez-Bussy, Sebastian , Barrios‐Ruiz, Alanna , Abia‐Trujillo, David

Respirology Case Reports | May 9, 2024 | Volume: 12 | Issue: 5 | Pages: No page available

10.1002/rcr2.1367 | PMID 38725709 Get It

AbstractExpiratory central airway collapse (ECAC) comprising excessive central airway collapse (EDAC) and tracheobronchomalacia. Treatment is challenging for severe cases that are not candidates for surgical management. We report a case of severe ECAC successfully managed with continuous positive airway pressure (CPAP) therapy. A 75‐year‐old female patient status post right pneumonectomy, presented with chronic cough. Dynamic bronchoscopy evaluation showed severe EDAC which improved with intraprocedural noninvasive positive pressure (NIPPV) therapy. Due to patients' comorbidities, she was not a candidate to surgical tracheobronchoplasty. Therefore, we attempted pneumatic stenting with long‐term CPAP therapy resulting in improvement of symptoms and functional capacity. The long‐term efficacy of pneumatic stenting has not been clearly established yet. Literature review of management of ECAC with NIPPV consist primarily of case reports and there is only one clinical trial being conducted to assess the efficacy of CPAP therapy in ECAC. While NIPPV arises as a sufficient alternative for management of severe ECAC, larger scale studies are needed to prove the real efficacy of NIPPV in this setting.
Listening to patients, for the patients: The COVAD Study—Vision, organizational structure, and challenges
Joshi, Mrudula , Darooka, Naitica , Saha, Sreoshy , Dyball, Sarah , Sen, Parikshit , Yaadav, Praggya , Javaid, Mahnoor , Kadam, Esha , Shinjo, Samuel Katsuyuki , Dey, Dzifa , Gutiérrez, Carlos Enrique Toro , Caballero‐Uribe, Carlo V. , Kuwana, Masataka , Burmester, Gerd R , Ziadé, Nelly , Wincup, Chris , Parodis, Ioannis , Tan, Ai Lyn , Wang, Guochun , Dalbeth, Nicola , Velikova, Tsvetelina , Nikiphorou, Elena , Agarwal, Vikas , Gupta, Latika, group, the COVAD study, Tehozol, Erick Adrian Zamora , Alpizar-Rodriguez, D. , Singla, Shikha , Cheng, Karen Kow Yip , Gupta, Latika , Cavagna, Lorenzo , Makol, Ashima , Gutiérrez, Carlos Enrique Toro , Caballero-Uribe, Carlo Vinicio , Kuwana, Masataka , Burmester, Gerd-Rüdiger , Ziade, Nelly , Wincup, Chris , Andreoli, Laura , Parodis, Ioannis , Tan, Ai Lyn , Guillemin, Francis , Knitza, Johannes , Wang, Guochun , Dalbeth, Nicola , Velikova, Tsvetelina , Gracia-Ramos, Abraham Edgar , Nikiphorou, Elena , Day, Jessica , Chinoy, Hector , Aggarwal, Rohit , Agarwal, Vikas , Gupta, Latika , Joshi, Mrudula , Shinjo, Samuel Katsuyuki , Alpízar-Rodríguez, Deshiré , Zamora Tehozol, Erick Adrian , Dey, Dzifa , Sen, Parikshit , Saha, Sreoshy , Darooka, Naitica , Yaadav, Praggya , Cheng, Karen , Kadam, Esha , Makol, Ashima , Andréoli, Laura , Gracia‐Ramos, Abraham Edgar , Day, Jessica , Chinoy, Hector , Aggarwal, Rohit , group, the COVAD study

International Journal of Rheumatic Diseases | May 9, 2024 | Volume: 27 | Issue: 5 | Pages: No page available

10.1111/1756-185x.15161 | PMID 38720408 Get It

AbstractBackgroundThe pandemic presented unique challenges for individuals with autoimmune and rheumatic diseases (AIRDs) due to their underlying condition, the effects of immunosuppressive treatments, and increased vaccine hesitancy.ObjectivesThe COVID‐19 vaccination in autoimmune diseases (COVAD) study, a series of ongoing, patient self‐reported surveys were conceived with the vision of being a unique tool to gather patient perspectives on AIRDs. It involved a multinational, multicenter collaborative effort amidst a global lockdown.MethodsLeveraging social media as a research tool, COVAD collected data using validated patient‐reported outcomes (PROs). The study, comprising a core team, steering committee, and global collaborators, facilitated data collection and analysis. A pilot‐tested, validated survey, featuring questions regarding COVID‐19 infection, vaccination and outcomes, patient demographics, and PROs was circulated to patients with AIRDs and healthy controls (HCs).DiscussionWe present the challenges encountered during this international collaborative project, including coordination, data management, funding constraints, language barriers, and authorship concerns, while highlighting the measures taken to address them.ConclusionCollaborative virtual models offer a dynamic new frontier in medical research and are vital to studying rare diseases. The COVAD study demonstrates the potential of online platforms for conducting large‐scale, patient‐focused research and underscores the importance of integrating patient perspective into clinical care. Care of patients is our central motivation, and it is essential to recognize their voices as equal stakeholders and valued partners in the study of the conditions that affect them.
Plausible role of INPP4A dysregulation in idiopathic pulmonary fibrosis
Arvind, Meghana , Gheware, Atish , Srivastava, Mousami , Agrawal, Anurag , Bhatraju, Naveen Kumar , Bhatraju, Naveen Kumar , Pattnaik, Bijay , Prakash, Y. S.

Physiological Reports | May 9, 2024 | Volume: 12 | Issue: 9 | Pages: No page available

10.14814/phy2.16032 | PMID 38720166 Get It

AbstractINPP4A has been shown to be involved in the regulation of cell proliferation and apoptosis of multiple cell types including fibroblasts. Previous reports from our group have demonstrated the role of inositol polyphosphate 4‐phosphatase Type I A (INPP4A) in these functions. Though existing evidences suggest a critical role for INPP4A in the maintenance of lung homeostasis, its role in chronic lung diseases is relatively under explored. In the current study, we made an attempt to understand the regulation of INPP4A in idiopathic pulmonary fibrosis (IPF). Through integration of relevant INPP4A gene expression data from public repositories with our results from in vitro experiments and mouse models, we show that INPP4A is altered in IPF. Interestingly, the direction of the change is dependent both on the disease stage and the region of the lung used. INPP4A was found to be upregulated when analyzed in lung sample representative of the whole lung, but was downregulated in the fibrotic regions of the lung. Similarly, INPP4A was found to be high, compared to controls, only in the early stage of the disease. Though the observed increase in INPP4A was found to be negatively correlated to physiological indices, FVC, and DLCO, of lung function, treatment with anti‐INPP4A antibody worsened the condition in bleomycin treated mice. These contrasting results taken together are suggestive of a nuanced regulation of INPP4A in IPF which is dependent on the disease stage, cellular state and extent of fibrosis in the lung region being analyzed.
Choice of Anesthetic Management Can Reduce the Use of Rescue Antiemetics After Bariatric Surgery but Effects Are Short-lived
Ghanem, Omar M. , Lu, Lauren , Salame, Marita , Schroeder, Darrell R. , Schroeder, Darrell , Šprung, Juraj , Warner, David O. , Weingarten, Toby N.

No container title available | May 9, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4282223/v1 Get It

Abstract Background Postoperative nausea and vomiting (PONV) is frequent after bariatric surgery. We hypothesized that when compared with a volatile-based technique incorporating propofol infusions, the need for rescue antiemetics would be reduced by the use of two strategies: 1) the addition of dexmedetomidine infusions, and 2) the avoidance of opioid and volatile anesthetics, and that this reduction would be observed in the PACU following PACU discharge. Methods In this retrospective observational study we included patients undergoing bariatric surgery from 2018–2022 who received one of three anesthetic strategies: 1) volatile anesthetic and propofol infusion (VOL + PROP), 2) VOL + PROP with the addition of dexmedetomidine (DEX), or 3) opioid-sparing total intravenous anesthesia (PROP + DEX). Inverse probability of treatment weighting analysis determined the association between the need for rescue-antiemetics in the PACU following PACU discharge. Results 332 patients received VOL + PROP, 354 VOL + PROP + DEX, and 166 PROP + DEX. PROP + DEX received fewer rescue antiemetics in PACU compared to VOL + PROP (11% vs 24%, P = 0.002), and VOL + PROP + DEX fewer compared to VOL + PROP (16% vs 24%, P = 0.023). This differential effect was limited to PACU stay; antiemetic use increased across all groups following PACU discharge until midnight (ranging from 38–46% across groups, P = 0.71) and through the first postoperative day (ranging from 47–57%, P = 0.20). Conclusions The benefit associated with two PONV prevention strategies, the addition of dexmedetomidine infusion or avoidance of opioid and volatile anesthetics, did not persist after PACU discharge. These findings highlight the challenge of PONV on postoperative wards, and the need for a novel multimodal team approach to mitigate this complication.
Self-scheduling Medical Visits in a Multispecialty, Multisite Medical Practice: Complexity, Challenges, and Successes
North, Frederick , Buss, Rebecca J , Nelson, Elissa M , Thompson, Matthew C , Garrison, Gregory M. , Crum, Brian A. , Buss, Rebecca , Pecina, Jennifer , Garrison, Gregory M , Crum, Brian A , Thompson, Matthew C , Pecina, Jennifer L.

Health Services Research and Managerial Epidemiology | May 9, 2024 | Volume: 11 | Issue: No issue available | Pages: No page available

10.1177/23333928241253126 | PMID 38736506 Get It

Background Self-scheduling of medical visits is becoming more common but the complexity of applying multiple requirements for self-scheduling has hampered implementation. Mayo Clinic implemented self-scheduling in 2019 and has been increasing its portfolio of self-schedulable visits since then. Our aim was to show measures quantifying the complexity associated with medical visit scheduling and to describe how opportunities and challenges of scheduling complexity apply in self-scheduling. Methods We examined scheduled visits from January 1, 2022, through August 24, 2023. For seven visit categories, we counted all unique visit types that were scheduled, for both staff-scheduled and self-scheduled. We examined counts of self-scheduled visit types to identify those with highest uptake during the study period. Results There were 9555 unique visit types associated with 20.8 M (million) completed visits. Self-scheduled visit types accounted for 4.0% (838,592/20,769,699) of the completed total visits. Of seven visit categories, self-scheduled established patient visits, testing visits, and procedure visits accounted for 93.5% (784,375/838,592) of all self-scheduled visits. Established patient visits in primary care (10 visit types) accounted for 273,007 (32.6%) of all self-scheduled visits. Testing visits (blood and urine testing, 2 visit types) accounted for 183,870 (21.9%) of all self-scheduled visits. Procedure visits for screening mammograms, bone mineral density, and immunizations (8 visit types) accounted for 147,358 (17.6%) of all self-scheduled visits. Conclusion Large numbers of unique visit types comprise a major challenge for self-scheduling. Some visit types are more suitable for self-scheduling. Guideline-based procedure visits such as screening mammograms, bone mineral density exams, and immunizations are examples of visits that have high volumes and can be standardized for self-scheduling. Established patient visits and laboratory testing visits also can be standardized for self-scheduling. Despite the successes, there remain thousands of specific visit types that may need some staff-scheduler intervention to properly schedule.
Exposure to hyperoxemia and mortality in cardiac intensive care unit patients
Alviar, Carlos L. , Metkus, Thomas S. , Miller, P. Elliott , Jentzer, Jacob C. , Diepen, Sean van , Kashani, Kianoush

European Heart Journal: Acute Cardiovascular Care | May 9, 2024 | Volume: 13 | Issue: Supplement_1 | Pages: No page available

10.1093/ehjacc/zuae036.138 Get It

Abstract Funding Acknowledgements None. Background Hyperoxemia (a high PaO2, i.e. &gt;200-300 mmHg) has been associated with adverse outcomes in general critical care settings as well as in acute cardiovascular care conditions. The association between hyperoxemia and mortality has not been characterized in the heterogeneous population admitted to the cardiac intensive care unit (CICU). We aimed to examine the association between hyperoxemia on CICU admission with in-hospital mortality. Methods We retrospectively analyzed Mayo Clinic CICU patients from January 2007 to April 2018. PaO2 closest on admission was analyzed as a continuous variable (per 100 mmHg) and categorized as: 60-100 mmHg (51.9%), 101-150 mmHg (28.6%), 151-200 mmHg (10.6%), 201-300 mmHg (6.4%), and &gt;300 mmHg (2.5%). Those without PaO2 on admission and those with hypoxemia were excluded. The primary outcome was all-cause in-hospital mortality evaluated using logistic regression, after adjusting for age, Charlson Comorbidity Index, M-CARS, and use of IMV and NIPPV. Results A total of 3,368 patients were included (median 70.3 years, 39.4% women). Admission diagnoses included ACS (37.0%, with 19.8% STEMI), HF (67.8%), shock (33.0%) and cardiac arrest (25.3%). Median admission PaO2 was 99 (IQR 78, 136) mmHg, with no difference in median PaO2 between hospital survivors and inpatient deaths (99 versus 98, p = 0.38). A J-shaped relationship was observed between admission PaO2 and in-hospital mortality (Figure A), with slightly higher mortality below 100 mmHg and incrementally higher mortality above this threshold (esp. at &gt;200 mmHg). The incremental association between higher PaO2 and mortality (adjusted OR 1.17 per 100 mmHg higher, 95% CI 1.01-1.34, P = 0.03) was focused in the highest PaO2 group (i.e., &gt;300 mmHg; Figure B). Conclusion Hyperoxia (esp. PaO2 &gt;300 mmHg) on CICU admission is associated with increased in-hospital mortality, demonstrating a J-shaped association with an inflection point of lowest mortality around 100 mmHg. Further studies are warranted to assess if specific oxygen targets influence outcomes in critically ill cardiac patients.
Global longitudinal strain as a predictor of mortality in patients with cardiogenic shock
Oh, Jae K. , Hansen, K B, Ito, Saki , Wiggers, Henrik , Oh, Jae K. , Jentzer, Jacob C.

European Heart Journal: Acute Cardiovascular Care | May 9, 2024 | Volume: 13 | Issue: Supplement_1 | Pages: No page available

10.1093/ehjacc/zuae036.119 Get It

Abstract Funding Acknowledgements Type of funding sources: Foundation. Main funding source(s): Aarhus University Dagmar Marshalls Fond. Background The assessment of left ventricular (LV) function through transthoracic echocardiography (TTE) is essential for guiding diagnosis and treatment in cases of cardiogenic shock (CS). Myocardial global longitudinal strain (GLS) provides an objective and reproducible measure of systolic function, independently predicting outcomes in acute heart failure, regardless of left ventricular ejection fraction (LVEF). However, whether assessment of GLS can predict mortality in patients with CS remains unknown. Purpose In this study, we aimed to evaluate the prognostic significance of GLS in patients with CS. Methods Data from cardiac intensive care unit (CICU) patients admitted between 2007 and 2018 with CS who received vasoactive agents and/or mechanical circulatory support were analysed. GLS (as absolute values) and biplane LVEF were measured via TTE performed within 24 hours of CICU admission. Patients with CS were categorised based on the GLS quartile: mild (GLS &gt;9.7%), moderate (7.0% &lt; GLS &lt;9.6%), severe (5.0% &lt; GLS &lt; 6.9%), and very severe (GLS ≤ 4.9%). CICU and in-hospital mortality were compared across GLS categories, and the relationship between GLS and mortality was assessed using multivariable logistic regression. Results The study included 626 patients with a median age of 68.6 years, a median LVEF of 31% (IQR 24 to 40%), and a median GLS of 7.0% (IQR 5.0 to 9.7%). In-hospital mortality was 29.1%. As GLS deteriorated, there was an increasing need for vasopressors (P&lt;0.001). Patients with progressively lower GLS exhibited significantly higher CICU and in-hospital mortality across the GLS quartiles (Figure A; P&lt;0.001). Patients in the severe (adjusted OR 2.67; p&lt;0.001) and very severe category (adjusted OR 3.54; P&lt;0.001) had significantly increased risk of in-hospital death compared with mild category. In multivariable analysis, every 1% decrease in GLS corresponded to a 14% higher risk of in-hospital mortality (P&lt;0.001). Finally, GLS outperformed LVEF for discrimination of in-hospital mortality (P=0.002), and when both measurements were included in the same multivariable model, only GLS remained significant. When patients were divided according to whether they had GLS and/or LVEF below the median value, patients with low GLS had higher mortality irrespective of the LVEF (Figure B). Conclusion In patients with CS, GLS assessment surpasses LVEF in its prognostic value and improves risk stratification. Routine evaluation of GLS should be considered for patients with CS.Figure AFigure B
Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy
Perez, Cesar A. , Guo, Wenji , Novaes, Jose A. Monteiro de Oliveira , Reis, Kaike Felix Dos, Price, Katharine A., McGarrah, Patrick W. , Rosenberg, Ari J.

American Society of Clinical Oncology Educational Book | May 8, 2024 | Volume: 44 | Issue: 3 | Pages: No page available

10.1200/edbk_433330 | PMID 38718318 Get It

The treatment for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) with immune checkpoint inhibitors (anti-PD1) with or without chemotherapy has led to an improvement in survival. Yet, despite this therapeutic advancement, only 15%-19% of patients remain alive at four years, highlighting the poor survival and unmet need for improved therapies for this patient population. Some of the key evolving novel therapeutics beyond anti-PD1 in R/M HNSCC have included therapeutic vaccine therapies, bispecific antibodies/fusion proteins and multitargeted kinase inhibitors, and antibody-drug conjugates (ADCs). Multiple concurrent investigations of novel therapeutics for patients with R/M HNSCC beyond anti-PD(L)1 inhibition are currently underway with some promising early results. Beyond immune checkpoint inhibition, novel immunotherapeutic strategies including therapeutic vaccines ranging from targeting human papillomavirus–specific epitopes to personalized neoantigen vaccines are ongoing with some early efficacy signals and large, randomized trials. Other novel weapons including bispecific antibodies, fusion proteins, and multitargeted kinase inhibitors leverage multiple concurrent targets and modulation of the tumor microenvironment to harness antitumor immunity and inhibition of protumorigenic signaling pathways with emerging promising results. Finally, as with other solid tumors, ADCs remain a promising therapeutic intervention either alone or in combination with immunotherapy for patients with R/M HNSCC. With early enthusiasm across novel therapies in R/M HNSCC, results of larger randomized trials in R/M HNSCC are eagerly awaited.
Academic Productivity in Ophthalmology and Its Correlation to National Economic Indicators Among the OECD Countries: A Bibliometric Analysis
Reitblat, Olga, Lerman, Tsahi T. , Dadon, Judith , Zlatkin, Rita , Bahar, Irit , Sella, Ruti , Reitblat, Olga

Ophthalmic Epidemiology | May 8, 2024 | Volume: 32 | Issue: 2 | Pages: 236-244

10.1080/09286586.2024.2343728 | PMID 38718101 Get It